Morningstar

Kardium Announces Publication of PULSAR Pivotal Trial Results in JACC

The Globe mapping and ablation catheter from Kardium. The multicenter pivotal trial demonstrated that the Globe System achieved durable pulmonary vein isolation (PVI) in 95% of veins with only one ...
ksn.com

Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration

88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year study ...
WKRG

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years

TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR ...
BioWorld

PULSAR gives Kardium legs in PFA horse race

With strong one-year results from the PULSAR trial, Kardium Inc. could soon be jockeying for third place in the race for pulsed field ablation market share. Boston Scientific Corp. clearly won the ...
Business Wire

Kardium Announces Publication of PULSAR Pivotal Trial Results in JACC

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., an emerging leader in advanced solutions for atrial fibrillation, is proud to announce the publication of the PULSAR clinical trial results ...